Celsion expands US trial for BPH (benigh prostatic hyperplasia) microwave therapy:
This article was originally published in Clinica
Celsion has received permission from the US FDA to expand the Phase I trial of its microwave treatment for relieving urinary obstruction in patients with benign prostatic hyperplasia. The microwave urethroplasty procedure will be tested on an additional 20 patients, following promising results from the initial 10 patients assessed in the trial. The study's protocol is designed to shorten treatment time and to simplify the software and hardware requirements for treatment delivery, said the Columbia, Maryland-based company.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.